Mortality and pre-hospitalization use of low-dose aspirin in COVID-19 patients with coronary artery disease

12/18 Pre-Exposure Prophylaxis study (treated before exposed to the virus)

Yuan et al., Journal of Cellular and Molecular Medicine, doi:10.1111/jcmm.16198 (Peer Reviewed)
Mortality and pre-hospitalization use of low-dose aspirin in COVID-19 patients with coronary artery disease

Source PDF Share Tweet

Retrospective 183 hospitalized patients in China, 52 taking low-dose aspirin prior to hospitalization, showing no significant difference with treatment.

Yuan et al., 12/18/2020, retrospective, China, Asia, peer-reviewed, 6 authors.

risk of death, 4.4% lower, RR 0.96, p = 0.89, treatment 11 of 52 (21.2%), control 29 of 131 (22.1%), odds ratio converted to relative risk, mutivariate.

Effect extraction follows pre-specified rules prioritizing more serious outcomes. For an individual study the most serious outcome may have a smaller number of events and lower statistical signficance, however this provides the strongest evidence for the most serious outcomes when combining the results of many trials.

All 7 studies All Outcomes

Please send us corrections, updates, or comments. Vaccines and treatments are both extremely valuable and complementary. All practical, effective, and safe means should be used. Elimination of COVID-19 is a race against viral evolution. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. Denying the efficacy of any method increases the risk of COVID-19 becoming endemic; and increases mortality, morbidity, and collateral damage. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. Treatment protocols for physicians are available from the FLCCC.

Submit